IPSC (Century Therapeutics) Kacepetan wutah bathi saben saham ing taun lumaku

The annual growth rate of net income per share, as illustrated by the GURU.Markets terminal chart, reflects the struggle for leadership in clinical trials for Century Therapeutics (IPSC). The business relies on a unique gene-editing system that blocks copy expansion. The production of mass-market drugs from iPSC cells makes treatment predictable and accessible. The value of -271.00 indicates the level of this metric, determining the issuer's real valuation.
Rincian metrik keuangan lan pasar Century Tx (IPSC)

Century Therapeutics focuses on a long-term R&D strategy and the development of cellular platforms guided by a strong scientific core. The eps_yy_co metric measures the annual percentage change in net income per share, reflecting the growth or decline rates of profitability. This metric allows an investor to identify value traps in a timely manner and assess operational efficiency. The current value of -271.00 serves as an indicator of market consensus. By analyzing the EPS YoY dynamics, one can forecast the sustainability of the company's capital.